Home > Boards > US Listed > Medical - Drugs > Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Corporation

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Ubertino Member Profile
 
Followed By 102
Posts 27,025
Boards Moderated 4
Alias Born 02/01/04
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/6/2019 12:28:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 7:35:51 AM
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 11/6/2019 7:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 11/5/2019 2:43:12 PM
Arbutus to Report Third Quarter 2019 Financial Results GlobeNewswire Inc. - 10/30/2019 7:30:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 4:16:56 PM
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepat... GlobeNewswire Inc. - 10/3/2019 4:05:00 PM
Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 9/26/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/26/2019 4:15:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:18:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:18:27 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/20/2019 4:18:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:17:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:17:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:17:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:16:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 4:16:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2019 4:10:06 PM
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors GlobeNewswire Inc. - 8/20/2019 4:05:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/9/2019 4:32:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 4:06:58 PM
Arbutus to Participate at Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/6/2019 7:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2019 12:30:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2019 11:33:14 AM
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/5/2019 7:30:00 AM
Ubertino   Friday, 09/22/17 05:30:51 PM
Re: None
Post # of 5226 
Arbutus Biopharma Corporation

_____________________

FORM 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): September 22, 2017

Arbutus Biopharma Corporation
(Exact Name of Registrant as Specified in Charter)

BRITISH COLUMBIA, CANADA 001-34949 980597776
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)


100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8
(Address of Principal Executive Offices) (Zip Code)
(604) 419-3200
(Registrant's telephone number, including area code)


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]



Item 8.01. Other Events.

On September 22, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


Exhibit 99.1 Press Release dated September 22, 2017


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arbutus Biopharma Corporation


Date: September 22, 2017 By: /s/ Bruce G. Cousins
Bruce G. Cousins
Executive Vice President and Chief Financial Officer

EXHIBIT 99.1

Arbutus Presents HBV Data at Upcoming Scientific Conferences

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.

Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA
Presentations Include:

RNA Interference: A New Tool in the Toolbox for Treatment of HBV by Amy Lee, Senior Director, Research
HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice President, Head of Biology
Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA
Presentation Includes:

RNAi Based Human Therapy for Chronic Hepatitis B Infection by Amy Lee, Senior Director, Research
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.

About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com

Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: ttolmie@arbutusbio.com

Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: david.schull@russopartnersllc.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist